{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:10:51Z","timestamp":1761498651414,"version":"build-2065373602"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bpg.2021.101760","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T20:25:06Z","timestamp":1625257506000},"page":"101760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Use of immunosuppression in non-transplant hepatology"],"prefix":"10.1016","volume":"54-55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-1333","authenticated-orcid":false,"given":"Vincenzo","family":"Ronca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber G.","family":"Bozward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye Htun","family":"Oo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2021.101760_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.643310","article-title":"Natural killer cells and regulatory T cells cross talk in hepatocellular carcinoma: exploring therapeutic options for the next decade","volume":"12","author":"Bozward","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib2","first-page":"357","article-title":"The hepatic microenvironment and regulatory T cells","author":"Osei-Bordom","year":"2020","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3748\/wjg.v24.i13.1373","article-title":"Dissecting the molecular pathophysiology of drug-induced liver injury","volume":"24","author":"Ye","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-010-9183-5","article-title":"Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management","volume":"4","author":"Oo","year":"2010","journal-title":"Hepatology International"},{"key":"10.1016\/j.bpg.2021.101760_bib5","first-page":"50","article-title":"Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: an Italian multicentre study","author":"Muratori","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2021.101760_bib6","first-page":"2","article-title":"Approach to the patient with acute severe autoimmune hepatitis","author":"Rahim","year":"2020","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2021.101760_bib7","first-page":"382","author":"Heneghan","year":"2013","journal-title":"Autoimmune hepatitis. The Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib8","first-page":"40","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","author":"Cook","year":"1971","journal-title":"QJM"},{"key":"10.1016\/j.bpg.2021.101760_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(84)91691-X","article-title":"Antigen specific suppressor cell function in autoimmune chronic active hepatitis","volume":"323","author":"Vento","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8278(85)80051-9","article-title":"HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis","volume":"1","author":"Nouri-Aria","year":"1985","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib11","first-page":"75","article-title":"Alteration in suppressor cell activity in chronic active hepatitis","author":"Hodgson","year":"1978","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.bpg.2021.101760_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib13","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4 + CD25 + regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","article-title":"Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis","volume":"25","author":"Longhi","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bpg.2021.101760_bib15","first-page":"57","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","author":"Peiseler","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/1573396310666141114230147","volume":"10","author":"Longhi","year":"2014","journal-title":"Autoimmune hepatitis. Current pediatric reviews"},{"key":"10.1016\/j.bpg.2021.101760_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","article-title":"Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib18","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis - update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.11.004","article-title":"Diego and Giorgina Vergani: the two hearts of translational autoimmunity","volume":"66","author":"Liberal","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bpg.2021.101760_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bpg.2021.101760_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.1800455","article-title":"Bidirectional cross-talk between biliary epithelium and Th17 cells promotes local Th17 expansion and bile duct proliferation in biliary liver diseases","volume":"203","author":"Jeffery","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2013.05.034","article-title":"Regulatory T-cell directed therapies in liver diseases","volume":"59","author":"Oo","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib24","article-title":"Autoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy","author":"Than","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology (2016)"},{"key":"10.1016\/j.bpg.2021.101760_bib25","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.28740","article-title":"Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure","volume":"64","author":"Cl\u00e0ria","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib26","first-page":"49","article-title":"Autoimmune hepatitis and its variant syndromes","author":"Ben-Ari","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib27","first-page":"125","article-title":"The variant forms of autoimmune hepatitis","author":"Czaja","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpg.2021.101760_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease","volume":"28","author":"Czaja","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib29","first-page":"27","article-title":"Diagnosis and management of the overlap syndromes of autoimmune hepatitis","author":"Czaja","year":"2013","journal-title":"Can J Gastroenterol"},{"year":"2012","series-title":"The overlap syndromes of autoimmune hepatitis","author":"Czaja","key":"10.1016\/j.bpg.2021.101760_bib30"},{"key":"10.1016\/j.bpg.2021.101760_bib31","first-page":"54","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib34","first-page":"102","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib35","first-page":"16","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bpg.2021.101760_bib36","first-page":"13","article-title":"IgG4-related hepatobiliary disease: an overview","author":"Culver","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/liv.12988","article-title":"Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications","volume":"36","author":"Dara","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.bpg.2021.101760_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury \u2014 types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2021.101760_bib39","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/0960327115606529","article-title":"The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury","volume":"34","author":"Tailor","year":"2015","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.bpg.2021.101760_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib41","first-page":"165","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"91","author":"Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib42","first-page":"12","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bpg.2021.101760_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.bpg.2021.101760_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0016-5085(52)80035-6","article-title":"Cortisone, ACTH and antibiotics in fulminant hepatitis","volume":"21","author":"Ducci","year":"1952","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib45","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.7326\/0003-4819-38-6-1134","article-title":"Adrenal hormone therapy in viral hepatitis. II. The effect of cortisone in the acute disease","volume":"38","author":"Evans","year":"1953","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpg.2021.101760_bib46","first-page":"258","article-title":"Corticosteroids in the treatment of acute hepatitis in coma","author":"Vmkjah","year":"1962","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(50)91498-X","article-title":"Effect of cortisone on early fibrosis of the liver in rats","volume":"259","author":"Aterman","year":"1950","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.9.3.270","article-title":"Effect of corticosteroid therapy on bromsulphthalein excretion in active chronic hepatitis","volume":"9","author":"Cook","year":"1968","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib49","first-page":"8","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","author":"Danielsson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101760_bib50","first-page":"127","article-title":"Glucocorticoid receptors: finding the middle ground","author":"Desmet","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpg.2021.101760_bib51","first-page":"18","article-title":"New insights into the cell- and tissue-specificity of glucocorticoid actions","author":"Quatrini","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-0173(96)00012-4","article-title":"The role of adrenocorticoids as modulators of immune function","volume":"23","author":"McEwen","year":"1997","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.bpg.2021.101760_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1549-8719.2000.tb00117.x","article-title":"The microcirculation and inflammation: site of action for glucocorticoids","volume":"7","author":"Perretti","year":"2000","journal-title":"Microcirculation"},{"key":"10.1016\/j.bpg.2021.101760_bib54","first-page":"583","article-title":"Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch","author":"Malcher-Lopes","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpg.2021.101760_bib56","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5085(03)01060-6","article-title":"American gastroenterological association medical position","volume":"125","author":"Association","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib57","first-page":"9","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib58","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2018.12.035","article-title":"Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis","volume":"17","author":"Pape","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib59","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib60","first-page":"163","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.bpg.2021.101760_bib61","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2021.101760_bib62","first-page":"2","article-title":"Alcoholic liver disease: a current molecular and clinical perspective","author":"Ohashi","year":"2018","journal-title":"Liver Research"},{"key":"10.1016\/j.bpg.2021.101760_bib63","first-page":"27","article-title":"Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials","author":"Rambaldi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101760_bib64","first-page":"36","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH","author":"Mathurin","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib65","first-page":"149","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib66","first-page":"36","article-title":"Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials","author":"Hmoud","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.bpg.2021.101760_bib67","first-page":"45","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib68","first-page":"59","article-title":"Steroid use in acute liver failure","author":"Karkhanis","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib69","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14195","article-title":"Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis","volume":"39","author":"Weber","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.bpg.2021.101760_bib70","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cgh.2017.02.007","article-title":"Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease","volume":"15","author":"Culver","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib71","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/gutjnl-2012-303617","article-title":"Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib72","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03602538508991433","article-title":"The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine","volume":"16","author":"Van Scoik","year":"1985","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.bpg.2021.101760_bib74","first-page":"56","article-title":"Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine","author":"Vernier-Massouille","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00008571-199208000-00002","article-title":"Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes","volume":"4","author":"Szumlanski","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bpg.2021.101760_bib76","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/art.1780401026","article-title":"Azathioprine\u2010induced severe pancytopenia due to a homozygous two\u2010point mutation of the thiopurine me","volume":"40","author":"Leipold","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2021.101760_bib77","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199510123331512","volume":"333","author":"zum B","year":"1995","journal-title":"Autoimmune hepatitis. New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.bpg.2021.101760_bib78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101760_bib79","first-page":"301","article-title":"Controlled trial OF prednisone and azathioprine IN active chronic hepatitis","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib80","first-page":"16","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib81","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.1840080414","article-title":"Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal","volume":"8","author":"Stellon","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib82","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bpg.2021.101760_bib83","article-title":"Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates","volume":"S0168-8278","author":"Candels","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib84","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib85","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.12223","article-title":"Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis","volume":"37","author":"De Boer","year":"2013","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.bpg.2021.101760_bib86","first-page":"38","article-title":"A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis","author":"Kennedy","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101760_bib87","first-page":"14","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","author":"H\u00fcbener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib88","first-page":"16","article-title":"Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis","author":"Legu\u00e9","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib89","first-page":"17","article-title":"Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine","author":"de Boer","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib90","first-page":"348","article-title":"Mycophenolate mofetil","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib91","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate mofetil","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib92","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bpg.2021.101760_bib93","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203315570685","article-title":"Mycophenolic acid upregulates miR-142-3P\/5P and miR-146a in lupus CD4+ T cells","volume":"24","author":"Tang","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.bpg.2021.101760_bib94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ndt\/13.1.160","article-title":"Suppression of the humoral immune response by mycophenolate mofetil","volume":"13","author":"Smith","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bpg.2021.101760_bib95","first-page":"146A","article-title":"Mycophenolate mofetil embryopathy may be dose and timing dependent","author":"Ang","year":"2008","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.bpg.2021.101760_bib96","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib97","first-page":"49","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101760_bib98","first-page":"49","article-title":"Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels","author":"Nicoll","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101760_bib99","first-page":"353","article-title":"Immunosuppressive strategies in transplantation","author":"Denton","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2021.101760_bib100","article-title":"Combination treatment of rheumatoid arthritis with cyclosporine and methotrexate","volume":"17","author":"Stein","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.bpg.2021.101760_bib101","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.1780390908","article-title":"Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A","volume":"39","author":"F","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2021.101760_bib102","first-page":"61","article-title":"Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy","volume":"23","author":"Landewe","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bpg.2021.101760_bib103","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3899\/jrheum.100041","article-title":"Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis","volume":"37","author":"Krathen","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bpg.2021.101760_bib104","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","article-title":"No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis","volume":"41","author":"van den Borne","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2021.101760_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007893.pub2","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2021.101760_bib106","first-page":"302","article-title":"Autoimmune hepatitis in children: experiences in a tertiary center","volume":"23","author":"Dehghani","year":"2013","journal-title":"Iran J Pediatr (Persian Ed)"},{"key":"10.1016\/j.bpg.2021.101760_bib107","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jim\u00e9nez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.bpg.2021.101760_bib108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatr"},{"key":"10.1016\/j.bpg.2021.101760_bib109","first-page":"973","article-title":"Cyclosporine induced biochemical remission in childhood autoimmune hepatitis","volume":"36","author":"Franulovi\u0107","year":"2012","journal-title":"Coll Antropol"},{"key":"10.1016\/j.bpg.2021.101760_bib110","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib112","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","article-title":"Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience","volume":"34","author":"Tannous","year":"2011","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.bpg.2021.101760_bib113","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"De Lemos-Bonotto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2021.101760_bib115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/00365521.2018.1551498","article-title":"A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis","volume":"54","author":"Hanouneh","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib116","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365521.2016.1236398","article-title":"The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience","volume":"52","author":"Al Taii","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101760_bib118","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2021.101760_bib119","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101760_bib120","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.jhepr.2020.100123","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2021.101760_bib121","first-page":"10","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","author":"Levin","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.bpg.2021.101760_bib122","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"volume":"vol. 29","year":"2020","author":"Bischoff","key":"10.1016\/j.bpg.2021.101760_bib123"},{"key":"10.1016\/j.bpg.2021.101760_bib124","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0006-291X(75)90482-9","article-title":"Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution","volume":"66","author":"Bose","year":"1975","journal-title":"BBRC (Biochem Biophys Res Commun)"},{"key":"10.1016\/j.bpg.2021.101760_bib125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.crohns.2010.12.007","article-title":"Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report","volume":"5","author":"Doyle","year":"2011","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.bpg.2021.101760_bib126","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","article-title":"Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis","volume":"187","author":"Ozorio","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.bpg.2021.101760_bib127","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2021.101760_bib128","first-page":"48","article-title":"Toward precision medicine in primary biliary cholangitis","author":"Carbone","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2021.101760_bib129","first-page":"13","article-title":"From pathogenesis to novel therapies in the treatment of primary biliary cholangitis","author":"Ronca","year":"2017","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib130","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2021.101760_bib131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","article-title":"Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","author":"Mells","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.bpg.2021.101760_bib132","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis","volume":"42","author":"Liu","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.bpg.2021.101760_bib133","first-page":"156","article-title":"Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population","author":"Rong","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib134","first-page":"157","article-title":"Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis","author":"Harada","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib135","first-page":"64","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101760_bib136","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"1","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.bpg.2021.101760_bib137","first-page":"1","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","author":"Oo","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bpg.2021.101760_bib138","first-page":"11","article-title":"Antigen-specific immunotherapy for treatment of autoimmune liver diseases","author":"Richardson","year":"2020","journal-title":"Front Immunol"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:03:13Z","timestamp":1761498193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691821000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":137,"alternative-id":["S1521691821000408"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101760","relation":{},"ISSN":["1521-6918"],"issn-type":[{"type":"print","value":"1521-6918"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of immunosuppression in non-transplant hepatology","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101760"}}